Effects of atorvastatin on apelin, visfatin (nampt), ghrelin and early carotid atherosclerosis in patients with type 2 diabetes

Effects of atorvastatin on apelin, visfatin (nampt), ghrelin and early carotid atherosclerosis in patients with type 2 diabetes

  • نوع فایل : کتاب
  • زبان : انگلیسی
  • مؤلف : Nikolaos P. E. Kadoglou Nikolaos Sailer Alkistis Kapelouzou Stylianos Lampropoulos Ioulia Vitta Alkiviadis Kostakis Christos D. Liap
  • چاپ و سال / کشور: 2011

Description

To investigate the influence of atrovastatin treatment on carotid intima-media thickness (CIMT) and serumlevels of novel adipokines, like apelin, visfatin (nampt), and ghrelin, in patients with type 2 diabetes mellitus (T2DM). 87 statin-free patients (50males) withT2DM, aged 55–70, but without carotid atherosclerotic plaqueswere initially enrolled. CIMT was assayed in all participants by ultrasound. Patients were then treated with atorvastatin (10–80 mg) to target LDL\100 mg/dl. Anthropometric parameters, blood pressure, glycemic and lipid profile, high-sensitivity CRP (hsCRP), insulin resistance (HOMA-IR), apelin, visfatin and ghrelin were measured at baseline and after 12 months. Atorvastatin treatment significantly improved lipid profile across with increased apelin (from 0.307 ± 0.130 pg/ml to 1.537 ± 0.427 pg/ml; P\0.001) and suppressed visfatin (from 21.54 ± 10.14 ng/ml to 15.13 ± 7.61 ng/ml; P = 0.002) serumlevels in our diabetic patients. Standard multiple regression analysis showed that the atorvastatin-induced increment in apelin was independently associated with changes in total cholesterol (b = –0.510, P = 0.030) and LDL-cholesterol (b = –0.590, P\0.001) (R2 = 0.449, P = 0.014), while the reduction of visfatin concentration was independently associated with the change in hsCRP (b = 0.589, P\0.001; R2 = 0.256, P = 0.006), after adjustment for age, sex and BMI. CIMT and ghrelin did not alter significantly after 12 months of atorvastatin treatment (NS).Among participants, high-dose (80 mg) rather than lowdose (10 mg) of atorvastatin treatment yielded greater (P\0.05) changes in apelin, visfatin and CIMT levels despite the final equivalent levels of LDL. Atorvastatin administration increased apelin and decreased visfatin serum levels significantly, without change of CIMT, in patients with T2DM. However, high-dose of atorvastatin exerted more favourable impact on adipokines and CIMT than low-dose. Our results implicate another important link between adiposity and atherosclerosis.
Acta Diabetol DOI 10.1007/s00592-011-0310-0 Received: 29 March 2011 / Accepted: 27 June 2011  Springer-Verlag 2011
اگر شما نسبت به این اثر یا عنوان محق هستید، لطفا از طریق "بخش تماس با ما" با ما تماس بگیرید و برای اطلاعات بیشتر، صفحه قوانین و مقررات را مطالعه نمایید.

دیدگاه کاربران


لطفا در این قسمت فقط نظر شخصی در مورد این عنوان را وارد نمایید و در صورتیکه مشکلی با دانلود یا استفاده از این فایل دارید در صفحه کاربری تیکت ثبت کنید.

بارگزاری